Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for HCC
DENVER, Colo., Jun 28, 2024 (247marketnews.com)- Carisma Therapeutics Inc. (Nasdaq:CARM) reported the nomination of the first development candidate, under its collaboration with Moderna, an in vivo CAR-M targeting Glypican-3 (“GPC3”) designed to treat solid tumors, including hepatocellular carcinoma (“HCC”), the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S.
Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma, stated, “The nomination of the first Development Candidate underscores our productive collaboration with Moderna to develop mRNA-based in vivo CAR-M cell therapies.
“The Development Candidate targets GPC3, a tumor antigen that is highly expressed in HCC. This milestone represents a significant step forward in the development of immunotherapies for solid tumors, and an advance for the in vivo cell therapy field.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (CARM)
- Lasers, Lungs & Leapfrogs: Innovation Sparks Market Moves as Healthcare Stocks Surge
- Today’s Top Performers: MoBot’s Market Review 09/02/25 08:00 AM
- Breaking News: MoBot’s Latest Update as of 08/29/25 07:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/29/25 06:00 PM
- MoBot alert highlights: NASDAQ: IFRX, NASDAQ: CARM, NASDAQ: ULCC, NASDAQ: HWH, NASDAQ: KAVL (08/29/25 05:00 PM)